Acurx Pharmaceuticals, Inc. to Post Q2 2024 Earnings of ($0.28) Per Share, HC Wainwright Forecasts (NASDAQ:ACXP)

Acurx Pharmaceuticals, Inc. (NASDAQ:ACXPFree Report) – Stock analysts at HC Wainwright reduced their Q2 2024 earnings per share estimates for shares of Acurx Pharmaceuticals in a research report issued on Thursday, May 16th. HC Wainwright analyst E. Arce now forecasts that the company will earn ($0.28) per share for the quarter, down from their prior estimate of ($0.20). HC Wainwright currently has a “Buy” rating and a $12.00 target price on the stock. The consensus estimate for Acurx Pharmaceuticals’ current full-year earnings is ($1.28) per share. HC Wainwright also issued estimates for Acurx Pharmaceuticals’ Q3 2024 earnings at ($0.26) EPS, Q4 2024 earnings at ($0.45) EPS, FY2024 earnings at ($1.28) EPS, FY2025 earnings at ($2.32) EPS, FY2026 earnings at ($3.42) EPS, FY2027 earnings at ($3.89) EPS and FY2028 earnings at ($4.11) EPS.

Acurx Pharmaceuticals (NASDAQ:ACXPGet Free Report) last released its quarterly earnings results on Friday, March 15th. The company reported ($0.38) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.12).

Acurx Pharmaceuticals Price Performance

Shares of ACXP opened at $2.25 on Monday. The company has a 50-day moving average of $2.14 and a two-hundred day moving average of $3.08. The stock has a market cap of $35.64 million, a price-to-earnings ratio of -1.91 and a beta of -1.79. Acurx Pharmaceuticals has a one year low of $1.17 and a one year high of $8.82.

Institutional Trading of Acurx Pharmaceuticals

A number of hedge funds have recently modified their holdings of the business. Prospect Financial Services LLC acquired a new stake in shares of Acurx Pharmaceuticals during the fourth quarter worth approximately $977,000. NBC Securities Inc. acquired a new stake in shares of Acurx Pharmaceuticals during the 1st quarter valued at $34,000. Finally, Sigma Planning Corp purchased a new position in shares of Acurx Pharmaceuticals during the 4th quarter valued at $38,000. Hedge funds and other institutional investors own 11.53% of the company’s stock.

Acurx Pharmaceuticals Company Profile

(Get Free Report)

Acurx Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections.

Further Reading

Earnings History and Estimates for Acurx Pharmaceuticals (NASDAQ:ACXP)

Receive News & Ratings for Acurx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acurx Pharmaceuticals and related companies with's FREE daily email newsletter.